FDA “Public Beware” Warning (1956)
What the warning said
The FDA warned the public that the treatment was worthless as a cancer cure and described its promotion as fraudulent. The warning was distributed widely, including through post offices.
Context
The campaign followed years of litigation and enforcement. In 1952, the Fifth Circuit had concluded that the clinic's efficacy representations were false and misleading on the record and directed an injunction. The warning therefore was not issued in a vacuum.
How to interpret it
The poster shows the regulator's position and communication strategy. Its rhetoric can be analyzed critically, but disagreement with the campaign does not establish that the regimen worked. Treatment efficacy still requires reliable clinical evidence.